

14.03 TRIGLYCERIDES – MEDIUM CHAIN, FORMULA
Oral liquid 500mL, 12
Nutrini Peptisorb[®]
PROTEIN FORMULA WITH CARBOHYDRATE, FAT,
VITAMINS and MINERALS
Oral liquid 500mL, 12
Nutrini Peptisorb Energy[®]
Nutricia Australia Pty Ltd.

1 Purpose of Application

1.1 The minor submission requested a change to the pack size and maximum quantities of Nutrini Peptisorb[®] and Nutrini Peptisorb Energy[®].

2 Requested Listing

2.1 The submission proposes a change to the pack size to the existing listings, and therefore a change to the maximum quantities.

2.2 The proposed changes in pack sizes and maximum quantities are summarised in Table 1 below:

Table 1. Summary of changes in pack sizes and maximum quantities.

Drug (brand name)	Current Form (Max Qty)	Proposed Form (Max Qty)	Current volume per MQ (mL)	Proposed volume per MQ (mL)	Current DPMQ	Proposed DPMQ
Triglycerides medium chain formula (Nutrini Peptisorb [®])	Oral liquid 500 mL pouches, 8 (MQ = 8)	Oral liquid 500 mL bottles, 12 (MQ = 5)	32,000	30,000	\$705.85	\$662.04
Protein formula with carbohydrate, fat, vitamins and minerals (Nutrini Peptisorb Energy [®])	Oral liquid 500 mL pouches, 8 (MQ = 10)	Oral liquid 500 mL bottles, 12 (MQ = 7)	40,000	42,000	\$1502.89	\$1574.24

Source: Tables 1 and 2 of the submission.

2.3 The submission indicated that the carton size for each product will change from 8 pouches to 12 bottles, which would require changes in their maximum quantities. The Secretariat notes that the nutritional composition of the products remains the same.

For more detail on PBAC's view, see section 5 PBAC outcome.

3 Background

- 3.1 Nutrini Peptisorb and Nutrini Peptisorb Energy were previously considered and recommended for listing by the PBAC at the March 2015 PBAC meeting and November 2016 PBAC meeting respectively.

For more detail on PBAC's view, see section 5 PBAC outcome.

4 Consideration of the evidence

Further consideration by the NPWP

- 4.1 The Nutritional Product Working Party (NPWP) advised the PBAC it supported the retention of these products on the PBS in their new pack sizes, however noted there may be a shortfall of 1-2 days treatment for some patients under the new reduced maximum quantity of Nutrini Peptisorb®. The NPWP also considered it may be appropriate for the utilisation of these products to be monitored to ensure the new listing provides adequate supply; or that the maximum quantity of packs to be increased to from 5 to 6, which would result in a volume of 36,000 mL per maximum quantity to permit an appropriate duration of therapy per prescription for all patients.

Utilisation and Financial Estimates

- 4.2 The sponsor argued the increase in dispensed price for the new pack size of Nutrini Peptisorb Energy would most likely be offset by a reduction in dispensed scripts due to the higher quantities dispensed per prescription. The PBAC noted that this modest reduction in prescriptions may not be realised, particularly if patients are at the upper end of the age range and consuming greater amounts of protein formula.

For more detail on PBAC's view, see section 5 PBAC outcome.

5 PBAC Outcome

- 5.1 The PBAC agreed with the change to the pack sizes and associated maximum quantities for triglycerides medium chain formula and protein formula (Nutrini Peptisorb® and Nutrini Peptisorb Energy®) processed by the Secretariat at the same price per gram of energy equivalence as the current listing.
- 5.2 The PBAC noted the NPWP's advice that the new package of Nutrini Peptisorb® will only provide a total volume of 30,000 mL, instead of 32,000mL per maximum quantity. Therefore, the PBAC requested the Department monitor the utilisation of Nutrini Peptisorb® 12 months following the change to listing to ensure patients are receiving sufficient supply under the revised maximum quantity and do not require additional prescriptions.
- 5.3 The PBAC noted the implementation of the request will constitute new listings on the PBS (with new item codes) due to item description requirements for nutritional products and further noted the items for the replaced pack sizes will be delisted.
- 5.4 The submission is not eligible for independent review as it received a positive

recommendation.

Outcome:

Recommended

6 Recommended listing

6.1 Add new form and maximum quantity listing as follows:

Drug (brand name)	Current Form (Max Qty)	Recommended Form (Max Qty)
Triglycerides medium chain formula (Nutrini Peptisorb®)	Oral liquid 500 mL pouches, 8 (MQ = 8)	Oral liquid 500 mL bottles, 12 (MQ = 5)
Protein formula with carbohydrate, fat, vitamins and minerals (Nutrini Peptisorb Energy®)	Oral liquid 500 mL pouches, 8 (MQ = 10)	Oral liquid 500 mL bottles, 12 (MQ = 7)

7 Context for Decision

The PBAC helps decide whether and, if so, how medicines should be subsidised in Australia. It considers submissions in this context. A PBAC decision not to recommend listing or not to recommend changing a listing does not represent a final PBAC view about the merits of the medicine. A company can resubmit to the PBAC or seek independent review of the PBAC decision.

8 Sponsor's Comment

The sponsor had no comment.